BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported

Published: Dec 30, 2021

Recently, the Indonesian information portal SUARA.COM, Netherlands The World News and other media released news: 12.4 million doses of adenovirus vector COVID-19 vaccine (KCONECAVAC) manufactured by Shenzhen Kangtai Biological Products Co., Ltd. arrived in Indonesia.

Up to now, more than 30 million doses of adenovirus vector COVID-19 vaccine (KCONECAVAC) have been exported to Indonesia, which is the largest export order among similar vaccine varieties (adenovirus vector COVID-19) in China.

On October 31, as reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd.. It is understood that this is China's second adenovirus vector COVID-19 vaccine approved for emergency use overseas. Another vaccine, inactivated COVID-19 vaccine (KCONVAC), manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was approved for EUA in China in May 2021. So BioKangtai has become the only vaccine enterprise in the world that has two different vaccines at the same time.

According to the laboratory research of Oxford University *, neutralizing antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant. One booster dose of adenovirus vector vaccine is vaccinated 6 months after the completion of basic immunization (2 doses), and the antibody level could be increased 6 times.

(PR Newswire, Shenzhen, December 30, 2021)

*References links:
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html

View original source:
https://www.prnasia.com/story/347098-1.shtml